dc.creatorLaiño, Jonathan Emiliano
dc.creatorVillena, Julio Cesar
dc.creatorSuvorov, A.
dc.creatorZelaya, María Hortensia del Rosario
dc.creatorOrtiz Moyano, Francisco Ramiro
dc.creatorSalva, Maria Susana
dc.creatorAlvarez, Gladis Susana
dc.date.accessioned2019-08-26T18:51:47Z
dc.date.accessioned2022-10-15T14:48:28Z
dc.date.available2019-08-26T18:51:47Z
dc.date.available2022-10-15T14:48:28Z
dc.date.created2019-08-26T18:51:47Z
dc.date.issued2018-11
dc.identifierLaiño, Jonathan Emiliano; Villena, Julio Cesar; Suvorov, A.; Zelaya, María Hortensia del Rosario; Ortiz Moyano, Francisco Ramiro; et al.; Nasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.; Public Library of Science; Plos One; 13; 11; 11-2018; 1-19
dc.identifier1932-6203
dc.identifierhttp://hdl.handle.net/11336/82128
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4398682
dc.description.abstractRespiratory tract infections and invasive disease caused by Streptococcus pneumoniae in high-risk groups are a major global health problem. Available human vaccines have reduced immunogenicity and low immunological memory in these populations, as well as high cost as a public health strategy in poor communities. In addition, no single pneumococcal protein antigen has been able to elicit protection comparable to that achieved using protein-polysaccharideconjugate vaccines. In this context, chimeric pneumococcal proteins raise as potential good vaccine candidates because of their simplicity of production and reduced cost. The aim of this work was to study whether the nasal immunization of infant mice with the recombinant chimeric pneumococcal protein (PSFP) was able to improve resistance to S. pneumoniae, and whether the immunomodulatory strain Lactobacillus rhamnosus CRL1505 or its cell wall (CW1505) could be used as effective mucosal adjuvants. Our results showed that the nasal immunization with PSPF improved pneumococcal-specific IgA and IgG levels in broncho-alveolar lavage (BAL), reduced lung bacterial counts, and avoided dissemination of pneumococci into the blood. Of interest, immunization with PSPF elicited cross-protective immunity against different pneumococcal serotypes. It was also observed that the nasal immunization of infant mice with PSPF+CW1505 significantly increased the production of pneumococcal-specific IgA and IgG in BAL, as well as IgM and IgG in serum when compared with PSPF alone. PSPF+CW1505 immunization also improved the reduction of pneumococcal lung colonization and its dissemination in to the bloodstream when compared to PSPF alone. Our results suggest that immunization with PSPF together with the cell wall of the immunomodulatory strain L. rhamnosus CRL1505 as a mucosal adjuvant could be an interesting alternative to improve protection against pneumococcal infection in children.
dc.languageeng
dc.publisherPublic Library of Science
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0206661
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://doi.org/10.1371/journal.pone.0206661
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLACTIC ACID BACTERIA
dc.subjectCHIMERIC PNEUMOCOCCAL PROTEIN
dc.subjectCELL WALL
dc.subjectIMMUNOBIOTIC BACTERIA
dc.titleNasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución